Roche

Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Investors Business Daily
MS
multiple sclerosis
Roche
Celgene
Novartis
Biogen
ozanimod
Gilenya
Ocrevus
Extavia
Flag link:
Diabetes drugmakers partner with mobile startups to boost patient engagement
Diabetes drugmakers partner with mobile startups to boost patient engagement
Medical Marketing and Media
diabetes
mobile apps
patients
Novo Nordisk
Glooko
Roche
mySugr
Flag link:
Poor test results for Roche cloud growth prospects
Poor test results for Roche cloud growth prospects
Yahoo/Reuters
Roche
biosimilars
Rituxan
Herceptin
Avastin
Flag link:
5 Big Pharma Stocks With the Best Drug Pipelines
5 Big Pharma Stocks With the Best Drug Pipelines
Motley Fool
Big Pharma
Roche
AstraZeneca
AbbVie
Gilead Sciences
JNJ
Flag link:
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
Endpoints
Roche
biosimilars
Avastin
Herceptin
ABP 215
Amgen
MYL-14010
Mylan Labs
Rituxan
Flag link:
Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab
Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab
Motley Fool
Shire
Roche
hemophilia
emicizumab
Flag link:
Why Drugmakers Aren’t Sweating the Next Wave of Patent Losses
Why Drugmakers Aren’t Sweating the Next Wave of Patent Losses
Bloomberg
patents
Roche
Sanofi
Eli Lilly
patent cliff
Flag link:
Prescribed Reading: I/O is the only game in town
Prescribed Reading: I/O is the only game in town
BioPharma Dive
immuno-oncology
Celgene
BeiGene
Endo International
Opana ER
Novartis
Orkambi
Vertex Pharmaceuticals
Merck
Bristol-Myers Squibb
Roche
Opdivo
Keytruda
Orencia
Flag link:
Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul
Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul
Bloomberg
rare disease
healthcare reform
Shire
Jazz Pharmaceuticals
Sanofi
Roche
Biogen
Alexion
Vertex Pharmaceuticals
Flag link:
Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Endpoints
Sanofi
Alnylam
clinical trials
fitusiran
hemophilia
Roche
emicizumab
Flag link:
Industry paid $8.2B to docs, hospitals last year
Industry paid $8.2B to docs, hospitals last year
BioPharma Dive
physicians
physician payments
Roche
Novartis
Pfizer
Flag link:
PTC and Roche report solid data for Spinraza rival
PTC and Roche report solid data for Spinraza rival
BioPharma Dive
PTC Therapeutics
Roche
Spinraza
Biogen
RG7916
SMA
spinal muscular atrophy
Flag link:
Roche buys mySugr diabetes app
Roche buys mySugr diabetes app
Drug Delivery Business News
Roche
mySugr
mobile apps
diabetes
devices
Flag link:
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Flag link:
Novartis scores second biosimilar approval in two weeks
Novartis scores second biosimilar approval in two weeks
BioPharma Dive
Novartis
biosimilars
Enbrel
Europe
Sandoz
Erelzi
Roche
Rituxan
Flag link:
Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger
Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger
Endpoints
Roche
hemophilia A
ACE910
emicizumab
clinical trials
Flag link:
Roche's Ocrevus racks up more positive MS data in relapsing and primary progressive forms
Roche's Ocrevus racks up more positive MS data in relapsing and primary progressive forms
Fierce Pharma
Roche
Ocrevus
MS
multiple sclerosis
Flag link:
FDA says yes to rapid-acting Rituxan
FDA says yes to rapid-acting Rituxan
BioPharma Dive
FDA
Roche
Rituxan Hycela
refractory follicular lymphoma
CLL
diffuse large B-cell lymphoma
Flag link:
Novartis wins another biosimilar round with an OK for its Rituxan copycat
Novartis wins another biosimilar round with an OK for its Rituxan copycat
Endpoints
Novartis
biosimilars
Rituxan
Roche
Sandoz
Flag link:
Pfizer, Roche and Aspen face South African probe into cancer drug prices
Pfizer, Roche and Aspen face South African probe into cancer drug prices
Reuters
Pfizer
Roche
Aspen Pharmacare
South Africa
drug pricing
Flag link: